Inhibition of both TLR7 and TLR9 in lupus prone mice lead to reduction of autoantibody production and amelioration of disease symptoms
作者单位：Dynavax Technologies2929 Seventh StreetSuite 100BerkeleyCA 94710USA Dynavax Technologies2929 Seventh StreetSuite 100BerkeleyCA 94710USA Dynavax Technologies2929 Seventh StreetSuite 100BerkeleyCA 94710USA Dynavax Technologies2929 Seventh StreetSuite 100BerkeleyCA 94710USA Dynavax Technologies2929 Seventh StreetSuite 100BerkeleyCA 94710USA
会议名称：《The 8th International Congress on SLE》
会议日期：2007年
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
摘 要：正Purpose:The presence of autoantibodies specific for nucleic acid-associated antigens is the hallmark of Systemic Lupus Erythematosus（SLE）.The implication of Toll-like receptor （TLR）-7 and TLR9 in the disease process has been increasingly scrutinized in both human and mouse systems, this latter by introducing either TLR9 or TLR7 deficiencies onto the MRL/lpr *** studies have lead to